Indian law firm Cyril Amarchand Mangaldas has published an analysis titled "Mirror, Mirror on the Wall: The Rise of Personalised Cosmetics Regimens in India," turning a compliance-focused spotlight on one of the fastest-moving commercial trends in the country's beauty market.

The intervention matters because of who is asking the question. Cyril Amarchand Mangaldas is one of India's largest full-service law firms, and its consumer and regulatory practices routinely advise multinationals on the Legal Metrology Act, the Drugs and Cosmetics Act 1940 and the Cosmetics Rules 2020. When a firm of that calibre devotes a dedicated briefing to personalised cosmetics, it usually signals that client demand for guidance has reached a level where the legal uncertainty itself has become a business issue.

Why does personalisation strain the existing framework?

The article's framing — "the rise of personalised cosmetics regimens" — points to the core tension. India regulates cosmetics through a pre-market approval and labelling regime built around standardised, mass-produced SKUs. Personalised regimens, by contrast, are assembled for an individual consumer, often after a questionnaire, skin assessment or diagnostic step.

That model sits awkwardly with rules written for fixed formulations:

• Label claims must match a declared, approved composition, which is harder to assert when the composition varies by customer.
• Import registration under the Cosmetics Rules 2020 presumes defined products crossing the border, not formulations configured at the point of sale.
• Consumer-protection and advertising rules require claim substantiation, which becomes harder when claims are tailored to one user.

The source publication does not disclose specific figures or case citations, and INCI File has not independently verified the briefing's full contents beyond its title and authorship. What is verifiable is the timing and the subject: a major Indian legal practice has formally flagged personalised cosmetics as a category requiring structured regulatory thinking.

What should formulators and compliance teams take from it?

For brands already selling or planning personalised regimens in India, the signal is procedural rather than substantive. Legal review of the personalisation mechanic — how the questionnaire maps to formulation choices, and how claims are generated — is now on the due-diligence checklist that advisers expect.

Procurement and regulatory teams should expect questions along three lines when they brief counsel:

• Whether a bespoke regimen constitutes a new "cosmetic" requiring separate notification for each variant, or whether a modular system can be registered once.
• How diagnostic or skin-analysis tools used to build the regimen are characterised — as marketing tools or as something approaching a medical device boundary.
• What labelling discipline applies to a product configured for one named consumer.

None of these questions has a settled answer in Indian practice, which is precisely why a firm like Cyril Amarchand Mangaldas is publishing on it.

What comes next?

The article itself did not announce any rulemaking, and no amendment to the Cosmetics Rules specific to personalisation is cited in the material available to INCI File. The category's trajectory in India will most likely be shaped by how the Drugs Controller General of India and state licensing authorities handle the first enforcement matters involving individualised formulations, and by how courts interpret claim substantiation for bespoke products under consumer-protection law.

Brands operating in the segment should watch for two data points: any clarification or guidance note from the Central Drugs Standard Control Organisation on personalised cosmetics, and the first reported regulatory action involving a bespoke-regimen brand. Either would convert today's legal commentary into tomorrow's compliance obligation.